Gilead challenges ViiV in resistant HIV, filing twice-yearly therapyGilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs Share XGilead challenges ViiV in resistant HIV, filing twice-yearly therapyhttps://pharmaphorum.com/news/gilead-challenges-viiv-in-resistant-hiv-filing-twice-yearly-therapy/
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirGilead Sciences has the data it was hoping for in a pivotal trial of lenacapavir, an HIV drug Share XData sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavirhttps://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/
